Idiopathic Pneumonia Syndrome Refractory to Ruxolitinib after Post-Transplant Cyclophosphamide-based Haploidentical Hematopoietic Stem Cell Transplantation: Lung Pathological Findings from an Autopsy Case

Ken Matsumoto, Keigo Fujishita*, Masayuki Matsuda, Satoshi Oka, Yuka Fujisawa, Toshi Imai, and Takuya Machida

Department of Hematology and Blood Transfusion, Kochi Health Sciences Center, Kochi 781-8555, Japan

A 69-year-old Japanese man with acute leukemia received post-transplant cyclophosphamide-based haploidentical stem cell transplantation (PTCY-haplo-SCT) but was readmitted with dyspnea and ground-glass-opacities of the lungs. Bronchoscopy showed inflammatory changes with no signs of infection. He received steroids but required intubation as his condition deteriorated. In addition to antithymocyte globulin and cyclophosphamide, we administered ruxolitinib but failed to save him. Autopsy findings revealed fibrotic nonspecific interstitial pneumonia (NSIP) without evidence of organizing pneumonia or infection. Thus, we diagnosed idiopathic pneumonia syndrome (IPS). As far as our knowledge, this is the first case of IPS with NSIP histology after PTCY-haplo-SCT.

Key words: idiopathic pneumonia syndrome, ruxolitinib, post-transplant cyclophosphamide-based haploidentical stem cell transplantation, nonspecific interstitial pneumonia

Received January 22, 2022; accepted April 26, 2022.

*Corresponding author. Phone: +81-88-837-3000; Fax: +81-88-837-6766
E-mail: tempestram@outlook.com (K.Fujishita)

Conflict of Interest Disclosures: No potential conflict of interest relevant to this article was reported.
We conducted PTCY-haplo-SCT from the patient's daughter as a donor since there were no human leukocyte antigens (HLA)-matched sibling or unrelated donors. At nine days before the transplantation, there was no ground-glass opacity (GGO) on chest computer tomography (CT). The conditioning regimen was a nonmyeloablative regimen consisting of fludarabine, intravenous busulfan for two days, and total body irradiation (TBI). The patient did not receive lung shielding because the dose of TBI was just 4 Grays (Gy). The GVHD prophylaxis consisted of cyclophosphamide (CY) on days 3 and 4 and mycophenolate mofetil (MMF) plus continuous intravenous tacrolimus (TAC) from day 5 respectively. To minimize the risk of CY-induced cardiomyopathy and the risk of relapse, we reduced the dose of CY from 50 mg/kg for two days as first reported by Johns Hopkins University to 40 mg/kg for two days in accord with the JSCT Haplo16 study conducted by the Japan Study Group for Cell Therapy and Transplantation (JSCT) [6, 7]. The donor source was a peripheral blood stem cell.

The patient developed bacterial pneumonia on day 17 after transplantation, but the symptom resolved after engraftment. A bone marrow examination on day 27 confirmed complete remission, but skin erythema and dry cough appeared during the same period. A skin biopsy enabled a diagnosis of acute GVHD, but its severity was mild, classified as grade II based on the world consensus grading [8]. On day 28 and day 39, CT revealed GGOs newly emerging bilaterally (Fig. 1A-D). We suspected that the affected lung lesions were organizing pneumonia (OP) because some of the GGOs migrated. Indeed, the GGOs regressed after we increased the dose of TAC.

Since the skin erythema with acute GVHD and dry cough also resolved, we did not administer steroids, and he was discharged on day 70. Although skin erythema recurred at a regular visit on day 83, the GGOs further regressed on CT (Fig. 1E, F). Nevertheless, he had to be admitted with an acute respiratory impairment only one week later.

The physical examination at admission showed erythema with itching mainly on the face and limbs, and auscultation revealed late inspiratory crackles in the basal dorsal lung lesion bilaterally. A complete blood count showed mild thrombocytopenia and anemia, which was unchanged from a week ago. On the other hand, biochemical examination revealed elevations of lactate dehydrogenase (LDH) and C-reactive protein (CRP) compared to the week ago, suggesting inflammation. In contrast, the cytomegalovirus (CMV) antigen was negative, and a trough level of TAC was 4.2 ng/mL, similar to that observed at the previous week. CT showed re-exacerbation of the GGOs in the lower lungs lobe bilaterally (Fig. 2A, B).

In bronchoscopy, the bronchoalveolar lavage fluid (BAL) with a recovery rate of 48% showed an increased cell number at 510 /µL, with an increased lymphocyte ratio of 50%, 84% of which were CD8-positive T cells. On the other hand, a polymerase chain reaction (PCR) test for Pneumocystis jirovecii and the galactomannan
antigen in the BAL were negative.

A transbronchial lung biopsy showed no intraluminal plugs in the alveoli, but edematous hypertrophic alveolar septa and mild lymphocyte infiltration. There were no pathological findings of infection, with negative immunostaining for CMV and Grocott staining. We also performed a loop-mediated isothermal amplification test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), with a negative result.

We diagnosed the re-exacerbation of OP accompanied by acute GVHD because the GGOs had been observed before and re-emerged along with the recurrence of skin erythema. The increased lymphocyte ratio in the BAL also indicated immunological mechanisms. Since the patient was not in respiratory failure yet, we started prednisolone of 30 mg/day on the day after his admission (day 91 after transplantation).

However, he lapsed into rapid respiratory failure in the early morning on the third day of admission (day 92). Laboratory studies showed a further increase in LDH, and CT showed a rapid exacerbation of GGOs (Fig. 2C, D). While there were no signs of heart failure, the value of Krebs von den Lungen-6 (KL-6) had increased to 527 U/mL, suggesting pulmonary fibrosis. We diagnosed refractory OP and performed steroid pulse therapy. We also changed the route of tacrolimus from oral to a continuous intravenous administration. Nevertheless, the patient required intubation as the respiratory distress progressed on the fourth day of admission (day 93).

According to the second-line treatment of acute GVHD, we added 1 mg/kg of antithymocyte globulin (ATG), which improved his respiratory condition. We managed to decannulate him as his respiratory condition improved. Nevertheless, oxygen saturation already began to worsen again the day after the decannulation. Since the lymphocytes in the peripheral blood increased as his respiratory condition deteriorated, we considered that suppressing alloreactive T cells was insufficient and re-administered ATG 1 mg/kg and added MMF. However, the CT taken on two days after the re-administration of ATG (day 101) showed further expansion of the GGOs (Fig. 2E, F). As a treatment of acute interstitial pneumonia, we performed pulse therapy with CY, but it had no effect. We considered that refractory acute GVHD participated in the pathogenesis because the patient’s respiratory symptoms appeared along with recurrence of the skin erythema. Due to the pandemic of COVID-19, mesenchymal stromal cells (MSC) were unavailable. Therefore, we started ruxolitinib 20 mg/day for the GGOs, with the approval of the ethical committee in our institution (No: 203007). Nevertheless, the respiratory condition deteriorated, and we had to re-intubate him. We administered steroid and CY pulse therapy again, but the oxygen saturation declined, and multiorgan failure reared. The patient died on the 33rd day of admission (day 122).

A pathological autopsy of the lungs revealed uniform thickening of alveolar septa throughout the tissue, with little inflammatory cell infiltration. There was a minimal alveolar structural alteration, and those findings were consistent with fibrotic nonspecific interstitial

![Fig. 2 (A,B): CT on admission, showing re-exacerbation of GGOs in the lower lung lobe bilaterally (arrows). (C,D): Chest CT findings on the third day of admission, showing a further exacerbation of GGOs (arrows). (E,F): Chest CT findings on two days after the re-administration of antithymocyte globulin, showing GGOs spread all over the lungs.](image-url)
pneumonia (NSIP) (Fig. 3A, B). There were also findings similar to those of usual interstitial pneumonia (UIP) in the subpleural lesion and the margins of the lower lobes, such as spatially heterogeneous fibrosis accompanied by alteration of the alveolar structure and microscopic honeycomb change (Fig. 3C, D). Also, diffuse alveolar damage (DAD) except for the fibrotic stage was observed in some parts of the lungs (Fig. 3E, F). By contrast, there were no findings suggestive of OP or acute fibrinous OP such as granulomas, Masson body, intraluminal polyps, or fibrin deposition in the alveolar space. Besides, there were no findings of infections.

To summarize, the GGOs that appeared after PTCY-haplo-SCT exacerbated at months after the...
engraftment. The histological evaluation revealed mainly NSIP as well as, in some parts, UIP and DAD.

Thus, we diagnosed his non-infectious pulmonary complication as IPS, according to the National Heart, Lung, and Blood Institute consensus definition, rather than OP or peri-engraftment respiratory distress syndrome [1].

**Discussion**

IPS is one of the non-infectious post-transplant pulmonary complications, which is defined by the following criteria: (1) widespread alveolar injury, (2) absence of a lower respiratory tract infection, and (3) absence of pulmonary disorder due to cardiac dysfunction, acute renal failure, or iatrogenic overload [1]. IPS typically develops within 100 days, especially within one month after allo-SCT [1,9-11]. Known risk factors of IPS include myeloablative conditioning, TBI, acute GVHD, older age, and primary diseases such as AML and myelodysplastic syndrome [1,9,11].

The above-mentioned clinical features suggest that not only direct pulmonary damage from conditioning such as TBI, but also immune-mediated damage including GVHD, could lead to the onset of IPS. In animal models, researchers demonstrated that several humoral factors including tumor necrosis factor-alpha (TNF-α), lipopolysaccharides (LPS), chemokines, and oxidative stress can affect donor-derived T cells and antigen-presenting cells, causing IPS [1].

In our patient’s case, we speculate that bacterial pneumonia after the allo-SCT could have caused a high amount of LPS and chemokines release, which could have raised the risk of IPS. Besides, the use of TBI without lung shielding might have contributed to the development of IPS, as lung shielding during irradiation is reported to lower the IPS risk [11].

So far, all IPS that received histological evaluation are cases with non-PTCY-haplo-SCT, and DAD dominates most of the pathological findings, including 2 cases in Japan. [12-16]. We could not find a similar report in PubMed using the key phrases “idiopathic pneumonia syndrome”, “nonspecific interstitial pneumonia”, and “hematopoietic transplantation”.

Meanwhile, PTCY-haplo-SCT generally suppresses alloreactive immune reactions while preserving normal hematopoiesis since activated alloreactive T cells are generally fragile to CY due to having little aldehyde dehydrogenase (ALDH), which converts aldophosphamide, an active metabolite of CY, into an inactive metabolite carboxycyclophosphamide, whereas regulatory T cells (Tregs) and hematopoietic stem cells are resistant to CY because they are rich in ALDH [2]. In one clinical trial in Japan, the incidence of grade III-IV acute GVHD was only 5% after PTCY-haploidentical peripheral blood stem cell transplantation with a reduced-intensity conditioning regimen [17]. A meta-analysis also showed that PTCY-haplo-SCT was associated with a lower rate of GVHD compared with SCT from unrelated donors [18].

Thus, the most interesting point of this case is that severe IPS with rare histology developed after PTCY-haplo-SCT, without severe GVHD.

There are two theoretical reasons to consider regarding this patient’s development of IPS.

First, alloreactive T cells targeting pulmonary tissues had not might not have been depleted sufficiently since we reduced the dose of CY and used peripheral blood stem cell as a donor source.

A prospective study with a low-dose PTCY (25 mg/kg for one day) demonstrated that no less than 33% of the patients developed grade III–IV GVHD [19]. Furthermore, a meta-analysis reported an increase in immune-related complications such as GVHD when peripheral blood stem cells, with a large number of activated lymphocytes, were used as a donor source compared to bone marrow [20]. Hence, CY 40 mg/kg for two days with peripheral blood stem cell in our case was enough to prevent severe acute GVHD but was possibly insufficient to deplete alloreactive T cells causing the IPS.

Second, Tregs restraining pulmonary inflammation might have been specifically depleted, after the PTCY-haplo-SCT.

C-C motif chemokine ligand 2 (CCL2), also called monocyte chemotactic protein 1 (MCP1), is a chemokine that is released from lung tissue with inflammation [1]. CCL2 had been thought to develop pulmonary injury by recruiting T cells expressing C-C motif chemokine receptor 2 (CCR2) [1,21]. Meanwhile, recent studies have shown that CD4+ Forkhead box P3 (FoxP3)+Tregs expressing CCR2 strongly suppress inflammation and fibrosis in the lungs [22,23]. Furthermore, these Tregs expressing CCR2 are highly sensitive to CY [24].

Therefore, we infer that, in our case, Tregs express-
ing CCR2 were selectively depleted by PTCY, whereas bacterial pneumonia after allo-SCT drove CCL2 expression in lung tissue, which resulted in allogeneic T cells recruitment to lung tissue without suppression by the Tregs to develop fatal IPS. Since the expression of CCL2 of the lungs is enhanced in patients with NSIP or UIP, our patient's lung histology supports the above-mentioned hypothesis [25, 26].

There is also room for improvement in the treatment of IPS. The efficacy of steroids as an initial treatment for IPS is limited, and the mortality of IPS after one month is around 70% [1]. TNF-α inhibitors were expected as a second-line treatment, but a randomized controlled trial evaluating a TNF-α inhibitor for the treatment of IPS within 180 days after allo-SCT has failed to prove a statistically significant efficacy [27].

In our case, we administered ruxolitinib because the GGOs occurred along with skin GVHD. We presumed ruxolitinib to be effective against the lung lesions because ruxolitinib not only inhibits several inflammatory cytokines, including TNF-α, but also increases the number of Tregs [28].

There are some reports of ruxolitinib usage for non-infectious pulmonary complications after allo-SCT, especially obstructive bronchiolitis, which described some effects such as an improvement of respiratory function or a reduction of systemic steroids [29, 30]. However, we saw little pharmaceutical benefit in our patient.

Ruxolitinib could not restrain lung fibrosis sufficiently, partly because ruxolitinib mainly inhibits threacheal epithelial cells from releasing inflammatory cytokines, whereas it has a minor inhibitory effect on fibroblasts in lung tissue from proliferation and activation [31]. Additionally, ruxolitinib is known to downregulate the CCR2 expression on cells from patients with primary myelofibrosis [32]. Ruxolitinib increases the number of Tregs but may simultaneously suppress the expression of CCR2, which might have made it difficult for Tregs to migrate into the lung tissue in our case.

However, of the two cases of IPS after PTCY-haplo-SCT, one patient with IPS was effectively treated with ruxolitinib [33, 34]. One reason for the difference in clinical course between our case and the previous report is that the dose of PTCY was not reduced in the previous report, which could deplete allogeneic reactive T cells to some extent. In addition, the previous patient did not be contracted bacterial pneumonia before the IPS, and the amount of CCL2 in the lung could be smaller. Furthermore, concurrent administration of CY and ruxolitinib as a treatment for our patient's IPS might lead to further depletion of CCR2-positive Tregs and make the poorer prognosis.

Therefore, when clinicians are obliged to add treatment for refractory IPS after PTCY-haplo-SCT in addition to steroids and ruxolitinib, the use of MSC that increase CCR2-positive Tregs may be preferred over CY [23].

In conclusion, we encountered a patient with fatal IPS with rare histology of NSIP, which was refractory to ruxolitinib after PTCY-haplo-SCT.

Agents only to increase the number of Tregs, such as ruxolitinib, are not necessarily effective to IPS after PTCY-haplo-SCT, and we also need an approach to immigrate Tregs to the lung.

References


